Which has preferable earnings & valuation, IMVT or VCEL?

Vericel has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Vericel $276.26M 7.42 $16.52M $0.47 85.15

Is IMVT or VCEL more profitable?

Vericel has a net margin of 7.91% compared to Immunovant's net margin of 0.00%. Vericel's return on equity of 6.91% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Vericel 7.91% 6.91% 5.02%

Does the media refer more to IMVT or VCEL?

In the previous week, Immunovant had 1 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Immunovant and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Immunovant's score of 0.60 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, SYRE or VCEL?

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics $890K 8,917.51 -$155.20M -$1.95 N/A Vericel $276.26M 7.42 $16.52M $0.47 85.15

Does the media favor SYRE or VCEL?

In the previous week, Spyre Therapeutics had 5 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Spyre Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Spyre Therapeutics' score of 1.11 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, VCEL or ALKS?

Alkermes has higher revenue and earnings than Vericel. Vericel is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 7.42 $16.52M $0.47 85.15 Alkermes $1.48B 4.93 $241.66M $0.38 114.18

Is VCEL or ALKS more profitable?

Vericel has a net margin of 7.91% compared to Alkermes' net margin of 3.96%. Vericel's return on equity of 6.91% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.91% 6.91% 5.02% Alkermes 3.96% 4.15% 2.19%

Does the media refer more to VCEL or ALKS?

In the previous week, Alkermes had 6 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Alkermes and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Alkermes' score of 1.08 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VCEL or RYTM?

In the previous week, Rhythm Pharmaceuticals had 15 more articles in the media than Vericel. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, VCEL or SRRK?

Vericel has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 7.42 $16.52M $0.47 85.15 Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is VCEL or SRRK more profitable?

Vericel has a net margin of 7.91% compared to Scholar Rock's net margin of 0.00%. Vericel's return on equity of 6.91% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.91% 6.91% 5.02% Scholar Rock N/A -160.19% -87.18%

Does the media refer more to VCEL or SRRK?

In the previous week, Scholar Rock had 30 more articles in the media than Vericel. MarketBeat recorded 32 mentions for Scholar Rock and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Scholar Rock's score of 0.78 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 13 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Vericel (VCEL) Competitors

$40.02 -0.01 (-0.02%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$40.02 +0.00 (+0.01%)

As of 09/18/2026 07:30 PM Eastern

Compare

VCEL vs. IMVT, SYRE, ALKS, RYTM, and SRRK

Should you buy Vericel stock or one of its competitors? Vericel's main competitors and comparable companies include Immunovant (IMVT), Spyre Therapeutics (SYRE), Alkermes (ALKS), Rhythm Pharmaceuticals (RYTM), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vericel compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Vericel (NASDAQ:VCEL) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Vericel has a net margin of 7.91% compared to Immunovant's net margin of 0.00%. Vericel's return on equity of 6.91% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Vericel	7.91%	6.91%	5.02%

Immunovant has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Vericel has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Vericel has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Vericel	$276.26M	7.42	$16.52M	$0.47	85.15

Immunovant currently has a consensus price target of $44.00, indicating a potential upside of 19.08%. Vericel has a consensus price target of $58.40, indicating a potential upside of 45.93%. Given Vericel's stronger consensus rating and higher possible upside, analysts plainly believe Vericel is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

47.1% of Immunovant shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Immunovant had 1 more articles in the media than Vericel. MarketBeat recorded 3 mentions for Immunovant and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Immunovant's score of 0.60 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Vericel compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Vericel (NASDAQ:VCEL) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vericel has a net margin of 7.91% compared to Spyre Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Vericel	7.91%	6.91%	5.02%

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,917.51	-$155.20M	-$1.95	N/A
Vericel	$276.26M	7.42	$16.52M	$0.47	85.15

Spyre Therapeutics currently has a consensus price target of $109.69, indicating a potential upside of 21.54%. Vericel has a consensus price target of $58.40, indicating a potential upside of 45.93%. Given Vericel's higher possible upside, analysts clearly believe Vericel is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Spyre Therapeutics has a beta of 2.99, indicating that its share price is 199% more volatile than the broader market. Comparatively, Vericel has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 5 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Spyre Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Spyre Therapeutics' score of 1.11 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Alkermes?

Vericel (NASDAQ:VCEL) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Vericel has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Vericel has a net margin of 7.91% compared to Alkermes' net margin of 3.96%. Vericel's return on equity of 6.91% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Alkermes	3.96%	4.15%	2.19%

In the previous week, Alkermes had 6 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Alkermes and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Alkermes' score of 1.08 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has higher revenue and earnings than Vericel. Vericel is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.42	$16.52M	$0.47	85.15
Alkermes	$1.48B	4.93	$241.66M	$0.38	114.18

95.2% of Alkermes shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vericel currently has a consensus target price of $58.40, suggesting a potential upside of 45.93%. Alkermes has a consensus target price of $54.56, suggesting a potential upside of 25.75%. Given Vericel's higher probable upside, equities research analysts clearly believe Vericel is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alkermes	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78

Summary

Vericel beats Alkermes on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Rhythm Pharmaceuticals?

Vericel (NASDAQ:VCEL) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Vericel currently has a consensus target price of $58.40, indicating a potential upside of 45.93%. Rhythm Pharmaceuticals has a consensus target price of $140.67, indicating a potential upside of 43.96%. Given Vericel's higher probable upside, research analysts clearly believe Vericel is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

Vericel has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

Vericel has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.42	$16.52M	$0.47	85.15
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A

Vericel has a net margin of 7.91% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Vericel's return on equity of 6.91% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

In the previous week, Rhythm Pharmaceuticals had 15 more articles in the media than Vericel. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vericel beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Vericel compare to Scholar Rock?

Vericel (NASDAQ:VCEL) and Scholar Rock (NASDAQ:SRRK) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Vericel has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.42	$16.52M	$0.47	85.15
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Vericel currently has a consensus price target of $58.40, indicating a potential upside of 45.93%. Scholar Rock has a consensus price target of $66.00, indicating a potential upside of 41.48%. Given Vericel's higher possible upside, analysts plainly believe Vericel is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Scholar Rock	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.00

Vericel has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

91.1% of Scholar Rock shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 10.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Scholar Rock had 30 more articles in the media than Vericel. MarketBeat recorded 32 mentions for Scholar Rock and 2 mentions for Vericel. Vericel's average media sentiment score of 1.20 beat Scholar Rock's score of 0.78 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	13 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a net margin of 7.91% compared to Scholar Rock's net margin of 0.00%. Vericel's return on equity of 6.91% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Scholar Rock	N/A	-160.19%	-87.18%

Summary

Vericel beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.05B	$3.89B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	85.15	14.23	275.49	25.40
Price / Sales	7.42	1,419.61	646.01	89.45
Price / Cash	72.04	108.90	76.25	51.42
Price / Book	5.71	15.45	10.46	6.33
Net Income	$16.52M	-$22.86M	$3.49B	$358.33M
7 Day Performance	4.38%	-1.21%	0.59%	1.12%
1 Month Performance	-4.96%	-3.29%	-1.74%	-2.39%
1 Year Performance	26.33%	37.74%	18.13%	5.35%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	3.7317 of 5 stars	$40.02 0.0%	$58.40 +45.9%	+26.3%	$2.05B	$276.26M	85.15	398	Positive News High Trading Volume
IMVT Immunovant	2.2876 of 5 stars	$39.25 flat	$44.00 +12.1%	+150.0%	$8.11B	N/A	N/A	120
SYRE Spyre Therapeutics	2.7574 of 5 stars	$88.98 flat	$109.69 +23.3%	+506.5%	$7.82B	$890K	N/A	73	Positive News
ALKS Alkermes	3.5659 of 5 stars	$46.10 flat	$54.56 +18.4%	+56.1%	$7.73B	$1.48B	121.32	2,050	News Coverage Positive News Analyst Upgrade
RYTM Rhythm Pharmaceuticals	2.7685 of 5 stars	$102.74 flat	$141.12 +37.4%	+1.7%	$7.04B	$189.76M	N/A	140	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. IMVT, SYRE, ALKS, RYTM, and SRRK

How does Vericel compare to Immunovant?

Summary

How does Vericel compare to Spyre Therapeutics?

Summary

How does Vericel compare to Alkermes?

Summary

How does Vericel compare to Rhythm Pharmaceuticals?

Summary

How does Vericel compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. IMVT, SYRE, ALKS, RYTM, and SRRK

How does Vericel compare to Immunovant?

Is IMVT or VCEL more profitable?

Which has more volatility and risk, IMVT or VCEL?

Which has preferable earnings & valuation, IMVT or VCEL?

Do analysts prefer IMVT or VCEL?

Do insiders and institutionals have more ownership in IMVT or VCEL?

Does the media refer more to IMVT or VCEL?

Summary

How does Vericel compare to Spyre Therapeutics?

Do insiders and institutionals have more ownership in SYRE or VCEL?

Is SYRE or VCEL more profitable?

Which has preferable valuation and earnings, SYRE or VCEL?

Do analysts rate SYRE or VCEL?

Which has more risk and volatility, SYRE or VCEL?

Does the media favor SYRE or VCEL?

Summary

How does Vericel compare to Alkermes?

Which has more volatility and risk, VCEL or ALKS?

Is VCEL or ALKS more profitable?

Does the media refer more to VCEL or ALKS?

Which has preferable earnings and valuation, VCEL or ALKS?

Do insiders and institutionals have more ownership in VCEL or ALKS?

Do analysts rate VCEL or ALKS?

Summary

How does Vericel compare to Rhythm Pharmaceuticals?

Do analysts prefer VCEL or RYTM?

Which has more risk & volatility, VCEL or RYTM?

Which has stronger valuation & earnings, VCEL or RYTM?

Is VCEL or RYTM more profitable?

Does the media prefer VCEL or RYTM?

Summary

How does Vericel compare to Scholar Rock?

Which has preferable earnings and valuation, VCEL or SRRK?

Do analysts rate VCEL or SRRK?

Which has more risk and volatility, VCEL or SRRK?

Do institutionals and insiders believe in VCEL or SRRK?

Does the media refer more to VCEL or SRRK?

Is VCEL or SRRK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools